It’s only fair to share… Dabogratinib CAS 2800223-30-5 MF C25H24Cl2N6O3S, 559.5 g/mol 5-[(1R)-1-(3,5-dichloro-4-pyridinyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridinyl]-1H-indazole (R)-5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-3-(6-(6-(methylsulfonyl)-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-3-yl)-1H-indazole [6-(5-{5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl}pyridin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl](methyl)-λ6sulfanedioneTYRA-300fibroblast growth factor receptor inhibitor, antineoplastic, TYRA-300, TYRA 300, A1AV2, FH245S2JZJ Dabogratinib (TYRA-300) is an orally active, highly selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), designed to treat cancers with FGFR3 alterations and genetic diseases like achondroplasia. It shows potent tumor …
Author archives
Colfosceril miristate
It’s only fair to share… Colfosceril miristate CAS 18194-24-6 MF C36H72NO8P MW677.9325 1,2 Dimyristoyl glycero 3 phosphorylcholine (2R)-2,3-bis(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphatesurfactant replacement, DIMYRISTOYL LECITHIN, Dimyristoyllecithin, DMCP, DMPC Colfosceril miristate (1,2-dimyristoyl-sn-glycero-3-phosphocholine or DMPC) is a synthetic phospholipid commonly used in research to study lipid bilayers, liposomes, and drug delivery systems. It serves as a model membrane system due …
Claturafenib
It’s only fair to share… Claturafenib CAS 2754408-94-9 MF C18H15Cl2F2N5O3S MW490.3 g/mol N-[2-chloro-3-[(5-chloro-3-methyl-4-oxoquinazolin-6-yl)amino]-4-fluorophenyl]-3-fluoroazetidine-1-sulfonamide N-{2-chloro-3-[(5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]-4-fluorophenyl}-3-fluoroazetidine-1-sulfonamideB-Raf (BRAF) inhibitor, antineoplastic, PF-07799933, PF 07799933, ARRY440, ARRY 440, PC35M52J8T Claturafenib (development code PF-07799933) is an investigational cancer drug currently being developed by Pfizer. It is a selective, orally active pan-mutant BRAF inhibitor designed to treat advanced solid tumours with specific genetic alterations Mechanism of Action Claturafenib belongs …
Cirtociclib
It’s only fair to share… Cirtociclib CAS 2888704-84-3 MF C15H17F2N7O2 MW365.34 g/mol N-[3-(difluoromethoxy)-1H-pyrazol-5-yl]-1-(oxan-4-ylmethyl)pyrazolo[3,4-b]pyrazin-6-amine N-[5-(difluoromethoxy)-1H-pyrazol-3-yl]-1-[(oxan-4-yl)methyl]-1H-pyrazolo[3,4-b]pyrazin-6-aminecyclin-dependent kinase inhibitor, antineoplastic, BLU-222, BLU 222, BLU 170298, U93X72ED47, CDK2 Inhibitor BLU-222 Cirtociclib (also known as BLU-222) is an investigational drug that acts as a highly selective inhibitor of cyclin-dependent kinase 2 (CDK2). It is being developed by Blueprint Therapeutics for the treatment of advanced solid tumours, …
Ceperognastat
It’s only fair to share… Ceperognastat CAS 2241514-56-5 MF C16H22FN5O3S MW383.4 g/mol Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)- N-[4-fluoro-5-({(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl}methyl)-1,3-thiazol-2-yl]acetamideO-GlcNAcase (OGA) enzyme inhibitor, LY3372689, LY3372689, U0SGP6ZX2V Ceperognastat (LY3372689) is a drug candidate molecule under investigation to treat Alzheimer’s disease. It targets the enzyme O-GlcNAcase.[2][3] Its result is to reduce formation of tau protein tangles. A molecule containing radioactive fluorine was used with a PET scan to show that …
Cendifensine
It’s only fair to share… Cendifensine CAS 1034048-49-1 MF C14H17Cl2NO MW286.2 g/mol Methanone, (3,4-dichlorophenyl)[(3S)-3-propyl-3-pyrrolidinyl]- (3,4-dichlorophenyl)[(3S)-3-propylpyrrolidin-3-yl]methanonemonoamine reuptake inhibitor, NOE-115, NOE 115, N4U2JR8GCX, Cendifensine (INNTooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI)[1] related to the amphetamines and cathinones which has not been marketed at this time.[2][3][4] It was first described by 2013[4] and its INNTooltip International Nonproprietary Name was proposed in 2024.[2] The drug has been patented by Noema Pharma, which …
Catadegbrutinib
It’s only fair to share… Catadegbrutinib CAS 2736508-60-2 MF C47H54N12O4 MW851.0 g/mol 1,2,4-Oxadiazole-5-carboxamide, 3-(1,1-dimethylethyl)-N-[(1R)-1-[2-methyl-4-[6-[6-[4-[[1-[4-(tetrahydro-2,4-dioxo-1(2H)-pyrimidinyl)phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-3-pyridinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]ethyl]- 3-tert-butyl-N-[(1R)-1-[4-[6-[6-[4-[[1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-pyridinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylphenyl]ethyl]-1,2,4-oxadiazole-5-carboxamide 3-tert-butyl-N-{(1R)-1-[13-methyl-82,84-dioxo-27H-2(4,6)-pyrrolo[2,3-d]pyrimidina-8(1)-[1,3]diazinana-4(1,4)-piperazina3(5,2)-pyridina-6(4,1)-piperidina-1(1),7(1,4)-dibenzenaoctaphan-14-yl]ethyl}-1,2,4-oxadiazole-5-carboxamideBruton tyrosine kinase degrader, antineoplastic, BGB-16673, BGB 16673, PF6GPZ4DYT, BTK-IN-29, Tacabrutideg Catadegbrutinib (BGB-16673) is an orally active, potent Bruton’s tyrosine kinase (BTK) degrader, or chimeric degradation activator compound (CDAC). It works by targeting BTK for proteasomal degradation, showing high efficacy against wild-type and mutated forms (including C481S) …
Bretisilocin
It’s only fair to share… Bretisilocin CAS2698331-35-8 MF C13H17FN2 MW220.29 g/mol N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amineserotonin (5-HT2A) receptor agonist, GM-2505, GM 2505, 5-Fluoro-N-methyl-N-ethyltryptamine, 5F-MET, 5-F-MET, 5-Fluoro-MET, DS425RQ8SX Bretisilocin, also known by its developmental code name GM-2505 and as 5-fluoro-N-methyl-N-ethyltryptamine (5F-MET or 5-fluoro-MET), is a serotonergic psychedelic of the tryptamine family which is under development for the treatment of major depressive disorder.[1][7][2][3] It is an analogue of dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET).[8] Bretisilocin’s route of administration is intravenous infusion.[1][2][3][4] The …
Blixeprodil
It’s only fair to share… Blixeprodil CAS 2881017-49-6 MF C13H16FNO MW 221.27 g/mol Cyclohexanone, 2-(4-fluorophenyl)-2-(methylamino)-, (2R)- (2R)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-oneN-methyl-D-aspartate (NMDA) receptor antagonist, GM-1020, GM1020, (R)-4-Fluorodeschloroketamine, (R)-4-FDCK, (R)-4FDCK, S2MGG2PC5K Blixeprodil,[5] also known by its developmental code name GM-1020 or as (R)-4-fluorodeschloroketamine ((R)-4-FDCK), is an NMDA receptor antagonist related to ketamine which is under development for the treatment of major depressive disorder, bipolar depression, and other depressive disorders.[1][6][2][3][7][8] It is taken by mouth.[1][2][3] The …
Birelentinib
It’s only fair to share… Birelentinib CAS 2662512-15-2 MF C23H21F2N5O3 MW453.4 g/mol [(2S,5S)-5-[4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl]oxan-2-yl]methanol [(2S,5S)-5-{4-amino-5-[4-(2,3-difluorophenoxy)phenyl]imidazo[5,1-f][1,2,4]triazin-7-yl}oxan-2-yl]methanoltyrosine kinase inhibitor, antineoplastic, DZD8586, DZD 8586, Fast Track designation, BTK-IN-30, Z2F599L9GD Birelentinib (also known as DZD8586) is a first-in-class, non-covalent dual inhibitor of LYN (lymphocyte-specific protein tyrosine kinase) and BTK (Bruton’s tyrosine kinase). It is currently being developed by Dizal Pharmaceutical as an oral therapy for various B-cell malignancies. Clinical Status …